19365-07-2

Basic information

• Product Name: (R)-5-HYDROXY-PIPERIDIN-2-ONE
• Synonyms: 5-HYDROXY-2-PIPERIDONE;2-Piperidinone, 5-hydroxy-
• CAS NO: 19365-07-2
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13
• Product Categories: Piperidine
• Mol File: 19365-07-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 144-146 °C
• Boiling Point: 352.3 °C at 760 mmHg
• Flash Point: 166.8 °C
• Appearance: /
• Density: 1.199 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.21±0.20(Predicted)
• CAS DataBase Reference: (R)-5-HYDROXY-PIPERIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-5-HYDROXY-PIPERIDIN-2-ONE(19365-07-2)
• EPA Substance Registry System: (R)-5-HYDROXY-PIPERIDIN-2-ONE(19365-07-2)

Safety Data

• Hazardous Substances Data: 19365-07-2(Hazardous Substances Data)

Usage

General Description

(R)-5-Hydroxy-piperidin-2-one, also known as (R)-5-hydroxypiperidin-2-one or (R)-L-pyroglutamic acid, is a chemical compound with the molecular formula C5H9NO3. It is a cyclic organic compound containing a piperidine ring and a hydroxy group. (R)-5-HYDROXY-PIPERIDIN-2-ONE is a key intermediate in the biosynthesis of the neurotransmitter gamma-aminobutyric acid (GABA) and the amino acid proline. It is also used in the synthesis of various pharmaceuticals and as a chiral building block in organic chemistry. Additionally, (R)-5-Hydroxy-piperidin-2-one has potential applications in the development of new drugs and in the field of medicinal chemistry.

Upstream product

• 52065-78-8 piperidine-2,5-dione 
• 132210-73-2 N-(iodoacetyl)allylamine 
• 57859-04-8 (5-oxotetrahydrofuran-2-yl)methyl formate 
• 591-80-0 pent-4-enoic acid 
• 1179999-39-3 methyl 4-hydroxy-5-nitropentanoate 
• 179532-81-1 5-(azidomethyl)dihydrofuran-2(3H)-one 
• 10374-51-3 5-hydroxymethyl-4,5-dihydrofuranone 
• 4344-84-7 5-oxo-tetrahydro-furan-2-carboxylic acid 
• 617-65-2 Glutamic acid 
• 142-08-5 2-Pyridone 
• 5154-01-8 2,5-dihydroxypyridine 
• 19365-05-0 1,5-Dihydroxy-1H-2-pyridon 

Downstream Products

• 97899-35-9 2-piperidon-5-yl p-toluenesulfonate 
• 62414-68-0 (3R)-piperidin-3-ol 
• 24211-55-0 (S)-3-hydroxypiperidine 
• 143900-43-0 tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate 
• 52065-78-8 piperidine-2,5-dione 
• 124032-31-1 benzyl 6-hydroxy-4-azaspiro[2,5]octane-4-carboxylate 
• 87179-79-1 1-benzyl-5-(benzyloxy)piperidin-2-one 
• 1416946-24-1 6-oxopiperidin-3-yl((S)-(3-fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamate 
• 87179-80-4 1-benzyl-5-hydroxypiperidin-2-one 

Relevant articles and documents

A Three-Step Synthesis of δ-Aminolaevulinic Acid

Piperidine-2,5-dione (4) is prepared by catalytic hydrogenation of 5-hydroxy-2-pyridone (3).Ring opening of the lactam 4 with concentrated hydrochloric acid yields the hydrochloride of δ-aminolaevulinic acid (2).

CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR

Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof.

5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF

The present application discloses novel 5-aminopyrazole carboxamide compounds as shown in formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. In addition, the present application further discloses a method for the preparation of the compounds, a pharmaceutical composition comprising a compound of the invention and the use of the compounds.

TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS

Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have the above structure, where the definitions of the variables are provided herein.